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Abstract 
Background: Non-small cell lung cancer (NSCLC) is the most commonly diagnosed and fatal cancer worldwide. Scle-
rostin domain containing protein 1 (SOSTDC1) has been found to be tumor-suppressive in several types of cancers. 
However, the expression level and biological functions of SOSTDC1 in NSCLC remain unknown. Our current study 
aimed to identify the biological significance of SOSTDC1 in NSCLC.
Results: We found that SOSTDC1 was significantly down-regulated in NSCLC. Moreover, patients with higher expres-
sion of SOSTDC1 had a significant better prognosis than those with lower SOSTDC1 expression. Ectopic expression of 
SOSTDC1 in NSCLC cell lines A549 and NCI-H520 could inhibit proliferation as shown by MTT, colony formation, soft 
agar and EdU incorporation assays in vitro. Furthermore, A549 cells stably expressing ectopic SOSTDC1 grew more 
slowly and formed smaller tumors than vector-control cells in vivo. Mechanistic studies demonstrated that SOSTDC1 
over-expression led to increased p21Cip and p27Kip levels, thereby decreasing Rb phosphorylation status and E2F 
transcription activity.
Conclusions: SOSTDC1 is down-regulated in NSCLC, and its expression level is indicative of clinical outcome of 
patients with the disease. SOSTDC1 might represent a tumor suppressor through inhibiting the proliferation of NSCLC 
cells by regulating p21Cip and p27Kip, which in turn affects Rb-E2F signaling.
Keywords: SOSTDC1, Non-small cell lung cancer, Proliferation, p21Cip, p27Kip
© 2016 Liu et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Lung cancer is one of the most commonly diagnosed 
cancer types worldwide and the leading cause of cancer-
related death [1, 2]. Non-small cell lung cancer (NSCLC), 
which includes squamous cell carcinoma (SCC), adeno-
carcinoma (AD), large cell carcinoma (LCC), and other 
less frequently diagnosed histological types, accounts 
for about 80  % of lung cancer cases [3]. While various 
therapeutic approaches, including surgical resection, 
chemo- and radio-therapies, have been applied in the 
management of NSCLC, the overall 5-year survival rate 
of NSCLC patients still remains at only 15 % [4]. Better 
understanding  of the genetic events and key molecules 
involved in NSCLC development and progression is 
needed for developing effective therapeutic strategies 
against the disease.
Sclerostin domain-containing protein 1 (SOSTDC1), 
an important regulator of cell signaling, has been found 
to contribute to several physiological and pathological 
processes [5, 6]. Accumulating evidence has revealed 
that SOSTDC1 might act as a tumor suppressor in many 
cancers. In wilms tumor, SOSTDC1 is lost as a result of a 
7p21 homozygous deletion, which led to accelerate angi-
ogenesis and activation of Wnt signaling [7]. The expres-
sion of SOSTDC1 is down-regulated in gastric cancer, 
and ectopic over-expression of SOSTDC1 in gastric 
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cancer cells suppressed cell proliferation, cell cycle pro-
gression and anchorage-independent growth [8]. Clausen 
et al. found that the expression of SOSTDC1 reduced in 
breast cancer and such a reduction correlated   to poor 
prognosis of patients with the disease [9]. They also dem-
onstrated that SOSTDC1 interfered with the signaling 
mediated by the Wnt3a, BMP-2, and BMP-7 pathways 
in breast cancer cells [10]. Moreover, down-regulation of 
SOSTDC1 was observed in renal cancer, and SOSTDC1 
could suppress the proliferation of renal cancer cells via 
regulating BMP and Wnt3a signaling [11]. Neverthe-
less, the expression pattern and biological significance of 
SOSTDC1 in NSCLC remains largely unknown.
Deregulation of cell cycle progression represents a key 
characteristic in many types of cancer [12]. Under physi-
ologically normal conditions, the cell cycle progression 
is elegantly regulated by cyclins and cyclin-dependent 
kinases (CDK) [13]. Of note, the activity of these mol-
ecules is restricted by the Cip/Kip family members 
[14–16], among which p21Cip and p27Kip are key func-
tional cell cycle inhibitors containing an N-terminal CDK 
inhibitory domain and prevent CDKs from phospho-
rylating Rb, thus restricting the E2F transcription activ-
ity [14–17]. Given that E2F is an essential transcription 
factor for the production of cell cycle regulatory genes, 
p21Cip and p27Kip induces G1 arrest. Moreover, p21Cip 
could directly interfere with DNA replication by inhibit-
ing PCNA [18]. Therefore, p21Cip and p27Kip are widely 
recognized as tumor suppressors, and their inactivation 
is frequently observed in various types of cancer, includ-
ing NSCLC [19, 20]. While functional inactivation of 
p21Cip and p27Kip occur frequently in cancer cells, the 
mechanisms involved in the reduction or loss of p21Cip 
and p27Kip functions remain to be further understood.
In the context of understanding the possible role of 
SOSTDC1 in NSCLC development and progression, our 
current study led to findings that the protein is down-reg-
ulated in NSCLC and might play a tumor-suppressive role.
Results
The expression of SOSTDC1 is down‑regulated in NSCLC
To determine whether the expression of SOSTDC1 in 
NSCLC is altered, we first analyzed 99 pairs of primary 
tumor (T) versus normal tissues (N) using RNASeqV2 
data sets for NSCLC deposited on the TCGA website 
(https://tcga-data.nci.nih.gov/tcga) [21] for SOSTDC1 
expression. Our results showed that SOSTDC1 was 
down-regulated in 90 tumor tissues as compared to their 
adjacent non-cancerous lung tissues (Fig. 1a). To further 
assess the expression level of SOSTDC1 in NSCLC, we 
examined the level of SOSTDC1 in 18 pairs of tumors and 
their adjacent non-cancerous lung tissues. In agreement 
with the TCGA data, decrease in SOSTDC1 mRNA levels 
was observed in most tumor tissues as compared with 
that in their adjacent non-tumorous lung tissues (Fig. 1b). 
Next, we investigated the protein levels of SOSTDC1 in 
the 128 clinical specimens by performing immunohisto-
chemistry (IHC) (Fig.  1c; Table  1). While no significant 
correlation between SOSTDC1 protein level and patient 
age (p  =  0.732), gender (p  =  0.150), pathologic type 
(p = 0.765), or N classification (p = 0.204) was found, the 
expression of SOSTDC1 significantly correlated to clini-
cal staging (p  =  0.010), and T classification (p  <  0.001) 
(Table  2). Kaplan–Meier analysis using the log-rank test 
was performed to assay the effect of SOSTDC1 expres-
sion on the survival of NSCLC patients, and the data 
showed that patients with low SOSTDC1 expression had 
poorer overall survival than the high-SOSTDC1 expres-
sion group (p  <  0.001) (Fig.  1d). Furthermore, the prog-
nostic value of SOSTDC1 protein quantity in different 
subgroups of NSCLC patients stratified according to the 
clinical staging was also determined. As shown in Fig. 1e, 
low SOSTDC1 expression significantly correlated  to 
shorter overall survival time in either the stage I–II sub-
group (n =  86, p =  0.004, log-rank) or the stage III–IV 
subgroup (n =  42, p =  0.007, log-rank). Taken together, 
these data suggest that down-regulation of SOSTDC1 in 
NSCLC patients indicates a poorer prognosis.  
Ectopic over‑expression of SOSTDC1 inhibits the 
proliferation of NSCLC cells
Next, we asked whether SOSTDC1 might play a role in the 
development and progression of the malignant phenotype 
of NSCLC cells. To this end, two NSCLC cell lines, includ-
ing the lung adenocarcinoma cell line A549 and the lung 
squamous carcinoma cell line NCI-H520 (H520), were 
used. SOSTDC1 was ectopically over-expressed in A549 
and H520 cells to generate stable cell lines, as confirmed 
by western blotting assay shown in Fig. 2a. As analyzed by 
MTT assay and shown in Fig. 2b, SOSTDC1 over-expres-
sion significantly repressed the cell viability of A549 and 
H520 cells, as compared with their corresponding control 
cells. Moreover, colony formation assay showed that the 
ability of both cell lines to form cellular colonies was sig-
nificantly suppressed upon SOSTDC1 over-expression in 
comparison with that of their corresponding vector-con-
trol cells (Fig. 2c, d). Furthermore, we assessed the effect 
of high SOSTDC1 expression on anchorage independent 
growth using soft agar assay, and the results showed that 
cells expressing SOSTDC1 formed remarkably fewer and 
smaller colonies than the vector-control cells (Fig. 2e). In 
addition, EdU assays also revealed that the percentage of 
EdU-positive cell population was lower in SOSTDC1-
over-expressed cells (Fig.  2f). The above data together 
indicate that SOSTDC1 over-expression significantly sup-
presses the proliferative ability of NSCLC cells.
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Ectopic over‑expression of SOSTDC1 induces p21Cip 
and p27Kip expression and decreases the transcriptional 
activity of E2F
To delineate the mechanism underlying the anti-prolifer-
ative effect of SOSTDC1 on NSCLC cells, the expression 
levels of cell cycle regulators were analyzed in SOSTDC1-
over-expressing cells. As demonstrated in Fig.  3a, no 
alterations in the quantities of CDK2, CDK4, CDK6, 
cyclin A2, cyclin B1, cyclin D1, cyclin D2, cyclin D3, cyc-
lin E1 and cyclin E2 were detected in NSCLC cell lines 
over-expressing ectopic SOSTDC1 when compared with 
the corresponding control cells. By contrast, the levels of 
both p21Cip1 and p27Kip1, two important CDKs inhibi-
tors, significantly increased in SOSTDC1-transduced 
Fig. 1 The expression of SOSTDC1 is down-regulated in NSCLC. a The expression of SOSTDC1 in 99 pairs of primary tumors versus paired non-
tumorous lung tissues using RNAseqV2 data sets deposited in the TCGA datasets. b Expression of SOSTDC1 in 18 paired tumors and adjacent 
non-tumorous lung tissues assessed by qRT-PCR. c Representative images of IHC assays on SOSTDC1 expression in NSCLC. d Kaplan–Meier analysis 
showing the overall survival of NSCLC patients. e Kaplan–Meier analysis showing the overall survival of NSCLC patients categorized according to the 
UICC clinical stage. Patient survival is significantly different between SOSTDC1 high- and low-expressing patients within subgroups of clinical stage 
I + II and III + IV
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A549 and H520 cells. Moreover, ectopic expression of 
SOSTDC1 in NSCLC cells markedly inhibited the phos-
phorylation of Rb at Ser608 and Ser807 residues as well 
(Fig. 3b). As dephosphorylation of Rb is involved in regu-
lating the transcriptional activity of E2F, we next tested 
whether SOSTDC1 could alter the transcriptional activ-
ity of E2F. As shown by our reporter assay illustrated in 
Fig. 3c, SOSTDC1 over-expression resulted in significant 
inhibition of the transactivating activity of E2F. Collec-
tively, these data suggest that SOSTDC1 upregulates 
p21Cip and p27Kip expression and modulates Rb-E2F 
signaling.
SOSTDC1 suppresses tumor growth in vivo
The in  vitro data that SOSTDC1 negatively regulates 
NSCLC cells proliferation prompted us to investigate 
whether SOSTDC1 can suppress tumorigenesis in  vivo 
either. To this end, 8 × 106 indicated NSCLC cells were 
subcutaneously inoculated into BALB/C nude mice 
(n = 5, respectively), and subcutaneous tumors volumes 
and weights were quantitatively analyzed. As shown in 
Fig.  4, over-expression of SOSTDC1 in NSCLC cells 
significantly inhibited tumor growth in  vivo, further 
supporting the role of SOSTDC1 in NSCLC as a tumor 
suppressor gene.
Discussion
In our current study, we find that SOSTDC1 expression 
is down-regulated in NSCLC, and that such an alteration 
of SOSTDC1 expression is associated with a poor clini-
cal outcome of NSCLC patients. We also demonstrate 
that SOSTDC1 might inhibit the proliferation of NSCLC 
cells, possibly through up-regulating p21Cip and p27Kip 
and subsequent suppression of Rb-E2F signaling.
It has been well demonstrated that SOSTDC1 is 
involved in the process of fetal development [22–25]. Of 
note, accumulating studies have revealed that SOSTDC1 
acts as a tumor suppressor in several types of cancers. 
For example, Clausen et  al. found that expression of 
SOSTDC1 was down-regulated in breast cancer but a 




 ≤56 66 (51.6)
 >56 62 (48.4)
Gender
 Male 90 (70.3)
 Female 38 (29.7)
Pathology
 Squamous cell carcinoma 44 (34.4)
 Adenocarcinoma 76 (59.4)
 Adenosquamous carcinoma 8 (6.2)
Clinical stage
 I 55 (43)
 II 31 (24.2)
 III 35 (27.3)
 IV 7 (5.5)
T classification
 T1 27 (21.1)
 T2 64 (50.0)
 T3 33 (25.8)
 T4 4 (3.1)
N classification
 N0 72 (56.2)
 N1 31 (24.2)
 N2 24 (18.8)
 N3 1 (0.8)
Distant metastasis
 Yes 7 (5.5)
 No 121 (94.5)
Table 2 Correlation between  the clinical pathologic fea-
tures and expression of SOSTDC1
Characteristics SOSTDC1 p value
Low High
Age (y)
 ≤56 45 21 0.732
 >56 44 18
Gender
 Male 66 24 0.150
 Female 23 15
Pathologic type
 Squamous cell carcinoma 32 12 0.765
 Adenocarcinoma 51 25
 Adenosquamous carcinoma 6 2
Clinical staging
 I 30 25 0.010
 II 23 8
 III 30 5
 IV 6 1
T classification
 T1 10 17 <0.001
 T2 46 18
 T3 29 4
 T4 4 0
N classification
 N0 45 27 0.204
 N1 23 8
 N2 20 4
 N3 1 0
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high SOSTDC1 expression correlates to better progno-
sis [10]. Furthermore, Blish et al. showed that SOSTDC-
1was expressed in human kidney tissues and significantly 
decreased in renal clear cell cancer [26]. Moreover, 
down-regulation of SOSTDC1 was also observed in thy-
roid cancer [27]. In NSCLC, several lines of evidence 
provided by our current study, including analysis of the 
public TCGA dataset, assessment of our fresh as well 
Fig. 2 Ectopic over-expression of SOSTDC1 inhibits the proliferation of NSCLC cells. a Protein expression of SOSTDC1 in A549 and H520 cells was 
analyzed by Western blotting assay. α-tubulin was used as a loading control. b MTT assay was conducted to investigate the effect of SOSTDC1 on 
the proliferation of indicated cells at the indicated time points. c and d Representative micrographs (c) and relative quantification (d) of colony for-
mation assays of indicated cells. e Representative images of anchorage-independent colonies formed by SOSTDC1-over-expressed cells. f Relative 
quantification of EdU incorporation assays. For b, d, and f, results are expressed as mean ± SD (n = 3), *p < 0.05
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Fig. 3 Ectopic over-expression of SOSTDC1 up-regulates the expression of p21Cip and p27Kip, and suppresses E2F transcriptional activity. a West-
ern blotting analysis was performed to detect the cell cycle regulators CDK2, CDK4, CDK6, cyclin A2, cyclin B1, cyclin D1, cyclin D2, cyclin D3, cyclin 
E1, cyclin E2, p21Cip1 and p27Kip1 in indicated cells. α-tubulin was used as a loading control. b Ectopic expression of SOSTDC1 in the studied cells 
significantly inhibited the phosphorylation of pRb at Ser608 and Ser807 residues. α-tubulin served as the sample loading control. c Over-expression 
of SOSTDC1 attenuates E2F transcriptional activity using E2F-luc reporter assay. Results are expressed as mean ± SD (n = 3), *p < 0.05
Fig. 4 SOSTDC1 suppresses tumor growth in vivo. a Representative image of subcutaneous tumors isolated from nude mice. b Quantitative analy-
sis of tumor volumes. c Quantitative analysis of tumor weights. The indicated tumor volumes and weights represent the mean ± SD of five animals 
in each group, *p < 0.05
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as archived clinical specimens and functional tests, has 
shown that SOSTDC1 is a down-regulated tumor sup-
pressor in NSCLC cells.
Of note, various mechanisms have been proposed to 
contribute to the down-regulation of SOSTDC1 in can-
cers. For example, previous reports have shown hyper-
methylation in SOSTDC1 promoter CpGs and epigenetic 
silencing of SOSTDC1 transcription via increased meth-
ylation in prostate cancer [9, 28]. Moreover, E4BP4, a 
transcriptional repressor, could bind to the promoter 
of SOSTDC1 gene and induce CpG hyper-methylation, 
thereby leading to repressed SOSTDC1 expression in 
breast cancer [8]. Intriguingly, genomic deletion also con-
tributes to decreased SOSTDC1 expression. Specifically, a 
7p21 homozygous deletion has been identified in 9 of 97 
Wilms tumor, resulting in loss of SOSTDC1 [7], and loss 
of heterozygosity at 7p has also been reported to cause 
SOSTDC1 reduction in clear cell renal cell carcinoma [26]. 
Nevertheless, the exact molecular mechanism underly-
ing the observed SOSTDC1 down-regulation in NSCLC 
is yet to be elucidated. Further studies are required to 
understand whether the aforementioned genomic and epi-
genetic alterations may also be responsible for the down-
regulation of this important tumor suppressor in NSCLC, 
which are underway in our laboratory.
The observed down-regulation of SOSTDC1 in 
NSCLC implicates that SOSTDC1 is likely to be bio-
logically involved in the development and progression of 
the disease. Indeed, our current data demonstrate that 
SOSTDC1 may be involved in regulating the proliferative 
capability of NSCLC cells, and that such an anti-prolifer-
ative function is associated with an upregulation of cell 
cycle-inhibitory factors p21Cip and p27Kip. In the light 
that p21Cip and p27Kip are both well recognized regula-
tors of the RB-E2F signaling and indeed our present study 
has indicated a possible role of SOSTDC1 in modulating 
this cell-cycle regulatory pathway, it will be of great inter-
est to further elucidate whether the observed changes of 
p21Cip and p27Kip is essential to the inhibitory effects of 
SOSTDC1 on cell proliferation. On the other hand, more 
systemic studies would be needed to explore whether 
other molecules or pathways are also involved in medi-
ating the tumor-suppressive function of SOSTDC1 in 
NSCLC.
Conclusions
SOSTDC1 is down-regulated and suppresses tumor 
growth in NSCLC. Down-regulation of SOSTDC1 is 
indicative of poor prognosis of the disease. The tumor 
suppressive function of SOSTDC1 is associated with 
upregulation of p21Cip and p27Kip, which may interfere 




Lung cancer cell lines, including A549 and H520, were 
obtained from American Type Culture Collection 
(ATCC), and maintained in DMEM medium (Invitro-
gen, Carlsbad, CA) supplemented with 10 % fetal bovine 
serum (HyClone, Logan, UT) and 1 % penicillin/strepto-
mycin (Invitrogen, Carlsbad, CA), as previously reported 
[29]. The authenticity of the cell lines were verified by 
short tandem repeat fingerprinting at Medicine Labora-
tory of Forensic Medicine Department of Sun Yat-Sen 
University (Guangzhou, China).
RNA extraction and real‑time PCR
Total RNA from tissues was extracted by the TRizol rea-
gent (Life Technologies, Gaithersburg, MD), and reverse 
transcription (RT) reactions and real-time polymerase 
chain reaction (PCR) were performed as described pre-
viously [29]. Primers were synthesized according to the 
following sequences: SOSTDC1 forward, 5′-CACGTT-
GAATCAAGCCAGAA-3′ and reverse, 5′-GATG-
TATTTGGTGGAACGCA-3′; and GAPDH forward, 
5′-GACTCATGACCACAGTCCATGC-3′ and reverse, 
5′-AGAGGCAGGGATGATGTTCTG-3′.
Plasmids and transfection
SOSTDC1 expression plasmid was generated by PCR 
sub-cloning human SOSTDC1 coding sequence into ret-
roviral transfer plasmid pQCXIP (Clontech, Palo Alto, 
CA) to generate plasmid pQCXIP-SOSTDC1. Retrovi-
ral production and infection were performed as we pre-
viously described, and stable cell lines were selected by 
treatment with 0.5 μg/ml puromycin for 10 days, begin-
ning at 48 h after infection [27, 30].
Western blotting analysis
Western blotting analysis was performed according to a 
standard method previously described [31], using anti-
SOSTDC1, anti-cyclin B1, anti-cyclin D3 (Abcam, Cam-
bridge, MA), anti-cyclin A2, anti-cyclin D1, anti-cyclin 
E1, anti-CDK4, anti-CDK6 (Epitomics, Burlingame, Cali-
fornia), anti-cyclin D2, anti-CDK2 (BD Pharmingen, San 
Diego, CA), anti-cyclin E2, anti-p21Cip1, anti-p27Kip1, 
anti-p-Rb Ser608, anti-p-Rb Ser807, anti-Rb (Cell Signal-
ing, Beverly, MA). When re-probing, blotted membranes 
were stripped and re-blotted with an anti-α-tubulin 
mouse monoclonal antibody (Sigma–Aldrich, St. Louis, 
MO) as a loading control.
3‑(4,5‑dimethyl‑2‑thiazolyl)‑2,5‑diphenyl‑2‑H‑tetrazolium 
bromide (MTT) assay
According to previous studies [27], cell viability was 
determined using an MTT assay. The cells were seeded 
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at a density of 5  ×  103 cells per well in 96-well plates. 
Subsequently at 1, 2, 3, 4, 5 and 6  days, 20  μl MTT 
(Sigma–Aldrich, St. Louis, MO) was added to each well 
and incubated for 4 h. The culture medium was removed, 
and 200  μl dimethyl sulfoxide (DMSO) (Amresco, 
Solon, Ohio) was added to each well. The plates were 
then shaken for 30 min, and the optical density (OD) at 
490  nm was measured using a microplate reader. Each 
experiment was performed in triplicates.
Colony formation assay
For the colony formation assay, cells were plated into 
6-well plates at the density of 500 per well. The cells were 
allowed to grow for 10 days and stained with crystal vio-
let. The plates were photographed and the numbers of 
colonies formed by indicated cells were quantified using 
the Quantity One software package (Bio-Rad, Hercules, 
CA). Each experiment was repeated for three times.
Soft agar colony formation assay
Two milliliters of 0.66 % agar medium was added to each 
well of six-well plates to form bottom agar. Three thou-
sand A549 cells and H520 cells were mixed with 2 ml of 
0.33  % agar medium and then layered onto the bottom 
agar and incubated at 37  °C in 5  % CO2, and 0.5  ml of 
culture medium was added every week to keep the soft 
agar from drying and to supply nutrition. After 2 weeks 
of culture, the numbers of colonies were counted using a 
Zeiss microscope (Carl Zeiss, Jena, Germany).
5‑ethynyl‑2′‑deoxyuridine (Edu) incorporation assay
To examine the degree of DNA synthesis, the Cell Light 
EdU DNA imaging kit (RiboBio Co., Guangzhou, China) 
was used. Briefly, cells were seeded in 24-well plates 
and exposed to EdU for 2 h, followed by fixation in 4 % 
paraformaldehyde and permeabilization in 0.5  % Triton 
X-100. Images were taken using a fluorescent microscope 
at 488  nm excitation. Each experiment was repeated 
independently for three times.
Luciferase reporter assay
The pE2F-TA-Luc reporter plasmid was purchased from 
the Clonetech Inc. (Mountain View, CA). Luciferase assay 
was performed as we previously described [32]. NSCLC 
cells were seeded in triplicate wells in 48-well plates 
and allowed to settle for 24  h. Two hundred nanogram 
of luciferase reporter plasmid or the control-luciferase 
plasmid, plus 5 ng of pRL-TK renilla plasmid (Promega, 
Madison, WI), was transfected into cells accompanied 
with indicated plasmid using the Lipofectamine 3000 
reagent (Invitrogen, Carlsbad, CA) by following the man-
ufacturer’s protocol. Dual Luciferase Reporter Assays 
were performed to test luciferase and renilla signals after 
48  h according to a protocol provided with the Dual 
Luciferase Reporter Assay Kit (Promega, Madison, WI) 
by the manufacturer.
Tumor specimens from patients
This study was conducted on a total of 128 paraffin-
embedded NSCLC specimens, which were histopatho-
logically and clinically diagnosed at the Sun Yat-Sen 
University Cancer Center from 2001 to 2006. The 18 
NSCLC specimens and matched adjacent non-can-
cerous lung tissues were frozen and stored in liquid 
nitrogen until further use, according to our previous 
reports [29, 33]. For the use of these clinical materi-
als for research purposes, prior patients’ consents and 
approval from the Institutional Research Ethics Com-
mittee were obtained.
Immunohistochemistry assays (IHC)
IHC analysis was performed to study altered pro-
tein expression in human paraffin-embedded NSCLC 
specimens. The procedure was carried out similarly 
to previously described methods [34]. Immunostain-
ing evaluations were performed independently by 
experimenters blinded to sample identity. The staining 
intensity was scored as follows: 0 (negative), 1 (weakly 
positive), 2 (moderately positive), and 3 (strongly posi-
tive). The percent positivity was also scored according 
to four categories 0 (<5  %), 1 (5–25  %), 2 (>25–50  %), 
3 (>50–75 %) and 4 (>75 %). Then the value of percent 
positivity score was multiplied by staining intensity 
score to generate final expression scores of SOSTDC1, 
which ranged from 0 to 12. The staining scores were 
defined as follows: low expression (score ≤ 2) and high 
expression (score ≥ 3).
In vivo tumorigenesis assay
Animal protocols were approved by the Ethical Commit-
tee of Sun Yat-sen University. BALB/c nude mice were 
injected sc with 8 × 106 indicated cells in 0.1 ml of PBS in 
the right flank. Tumor volumes were measured with cali-
pers and calculated by the formula: 0.52 × length in mil-
limeters × (width in millimeters)2. Thirty days later, mice 
were killed, and tumors were excised and weighed.
Statistical analysis
All statistical analyses were carried out using the SPSS 
19. 0 statistical software package. The Kaplan–Meier 
method was used to establish survival curves, and log-
rank test was applied for comparative analysis of differ-
ences in patient survival. All values represent at least 
three independent experiments and are expressed as the 
mean  ±  SD. Comparisons between groups for statisti-
cal significance were performed with a two-tailed paired 
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Student’s t test. In all cases, p < 0. 05 was considered sta-
tistically significant.
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